Emad Barsoum, MD
Interventional Cardiology · Plainfield, NJNPI 1922313907
Payments from drug & device makers
Across 178 payments — averaging $45.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Abbott$2K
- Boston Scientific$1K
- AstraZeneca$451
- Shockwave Medical, Inc$432
- Medtronic$279
- plus $2K from 24 others
What the payments were for
- Travel & lodging$6088%
- Food & beverage$7,40992%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 13 | $1,736 |
| Abbott | 48 | $1,575 |
| Boston Scientific | 11 | $1,088 |
| AstraZeneca | 12 | $451 |
| Shockwave Medical, Inc | 8 | $432 |
| Medtronic | 9 | $279 |
| Inari Medical, Inc. | 3 | $237 |
| Philips North America LLC | 1 | $233 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $223 |
| Cvrx, Inc. | 6 | $221 |
| Novo Nordisk | 12 | $213 |
| Cardiovascular Systems Inc. | 6 | $204 |
| Heartflow, Inc. | 2 | $173 |
| Amgen | 4 | $158 |
| Impulse Dynamics (USA) Inc. | 2 | $131 |
| Penumbra, Inc. | 1 | $109 |
| Boehringer Ingelheim | 6 | $103 |
| Pfizer | 5 | $84 |
| Atricure, Inc. | 2 | $63 |
| Baxter Healthcare | 2 | $46 |
| Bardy Diagnostics, Inc. | 3 | $39 |
| Edwards Lifesciences | 2 | $37 |
| Merck | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Vital Connect, Inc | 1 | $26 |
| Cordis US CORP. | 1 | $25 |
| Terumo Medical Corporation | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,430
- COROFLOW$240
- US Und$233
- FARXIGA$209
- FLOWTRIEVER CATHETER, S$180
- CT THROMBECTOMY SYSTEM KIT$180
- AMPLATZER AMULET$163
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$149
- FFRct$148
- WATCHMAN Access System$142
- Barostim Neo System$141
- GENERAL - THERAPIES$137
- EKOSONIC$133
- GENERAL VASCULAR ACCESS$130
- Coronary Orbital Atherectomy System$125
- AVEIR$124
- OPTIMIZER SMART SYSTEM$112
- Repatha$111
- OPTIS$111
- Indigo System$109
How this compares
$8,030 in reported general payments places this provider in the 40th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $57,767 |
| BrilintaTicagrelor | 23 | $21,096 |
| Atorvastatin Calcium | 137 | $1,459 |
| Metoprolol Succinate | 94 | $988 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $897 |
| Losartan Potassium | 98 | $735 |
| Carvedilol | 74 | $734 |
| ClopidogrelClopidogrel Bisulfate | 69 | $669 |
| Amlodipine Besylate | 77 | $495 |
| Midodrine Hcl | 12 | $425 |
| Metoprolol Tartrate | 51 | $371 |
| Hydralazine Hcl | 17 | $361 |
| Valsartan | 13 | $230 |
| Rosuvastatin Calcium | 18 | $177 |
| Furosemide | 30 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $57,76762 claims |
| AstraZenecaBrilinta | $451 | $21,09623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Plainfield
- Dinesh SingalSomerset$1.4M
- Ankitkumar PatelGlen Ridge$717K
- Matthew SayboltEatontown$671K
- Jaffar RazaSecaucus$537K
- Kintur SanghviBordentown$467K
- Ziad AbbudOcean$361K
- Ramin HastingsHasbrouck Heights$355K
- Ryan KapleHackensack$280K
- Haroon FarazTeaneck$269K
- Darshan GodkarCedar Knolls$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.